Oncobiomed is a biotechnology company focused on developing, commercializing and licensing technologies associated to cancer prevention, diagnosis and treatment.
It was founded in 2002 by researchers and doctors as a spin-off originated at University of Chile with the purpose of transferring innovations in the field of cancer immunotherapy to the market, as TAPCells and LycellvaxTM.
Constituted by highly qualified professionals, such as medical oncologists, clinical immunologists, biologists, biotechnologists, civil engineers, lawyers, oncology nurses and communications professionals, Oncobiomed has a multidisciplinary view and a close link with academia.
Innovative company which recently acquired LycellvaxTM rights. This new technology uses tumour lysates conditioned to treat different cancer types. Though still in an experimental phase, it shares scientific principles with TAPCells, and means an improvement since its production and inoculation is standardised and does not require the collection of blood from the patient.